Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | NAAA | Q02083 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12650598 | 0.95 | NAAA (0.66) | SMN1; SMN2NPC1RAB9ANAAAEPHX2 | |
| SCHEMBL20362840 | 0.94 | RAB9A (0.64) | SMN1; SMN2NPC1RAB9ANAAAEPHX2 | |
| SCHEMBL10099547 | 0.93 | NAAA (0.69) | SMN1; SMN2NPC1RAB9ANAAAEPHX2 | |
| SCHEMBL496789 | 0.89 | SMN1; SMN2 (0.81) | SMN1; SMN2NPC1RAB9ANAAAEPHX2 | |
| SCHEMBL10137835 | 0.88 | NPC1 (0.60) | SMN1; SMN2NPC1RAB9ANAAALMNA | |
| SCHEMBL27512265 | 0.88 | NAAA (0.61) | SMN1; SMN2NPC1RAB9ANAAAEPHX2 | |
| SCHEMBL23996124 | 0.87 | HDAC3 (0.59) | SMN1; SMN2NPC1RAB9ANAAAEPHX2 | |
| SCHEMBL14144651 | 0.87 | NAAA (0.59) | SMN1; SMN2NPC1RAB9ANAAAEPHX2 | |
| SCHEMBL7099696 | 0.87 | NAAA (0.59) | SMN1; SMN2NPC1RAB9ANAAAEPHX2 | |
| SCHEMBL14742811 | 0.87 | NAAA (0.59) | SMN1; SMN2NPC1RAB9ANAAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| WO-2022204288-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-08-17 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7531008-B2 | Use of at least one cationic cyanin derivative for dyeing the hair, composition containing it, process for treating keratin fibers using the composition, and device therefor | L'OREAL S.A. (FR) | 2009-05-12 | — | — | US | disclosed |
| US-7427301-B2 | Composition comprising at least one substituted carbocyanin derivative, process for treating keratin fibers using it, device therefor and use thereof | L'ORéAL S.A. (FR) | 2008-09-23 | — | — | US | disclosed |
| US-7425221-B2 | Composition comprising at least one substituted derivative of carbocyanine, method for treating keratin fibers using it, device and use | L'OREAL S.A. (FR) | 2008-09-16 | — | — | US | disclosed |
| US-7419511-B2 | Compositions comprising at least one substituted carbocyanin derivative, processes for treating keratin fibers using them, device therefor and uses thereof | L'OREAL, S.A. (FR) | 2008-09-02 | — | — | US | disclosed |
| US-7377946-B2 | Composition comprising at least one substituted 2-[2-(4-amino phenyl)ethenyl]-1-pyridinium derivative, process for treating keratin fibres using it, device and use thereof | L'ORÉAL (FR) | 2008-05-27 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070143936-A1 | Use of at least one cationic cyanin derivative for dyeing the hair, composition containing it, process for treating keratin fibers using the composition, and device therefor | L'OREAL S.A. (FR) | 2007-06-28 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | SMN1; SMN2 4114/4885NPC1 4593/4885RAB9A 2131/4885 |
| US-20070143936-A1 | Use of at least one cationic cyanin derivative for dyeing the hair, composition containing it, process for treating keratin fibers using the composition, and device therefor | KRT18, HKDC1, DSC1 | SMN1; SMN2 4875/4885NPC1 4258/4885RAB9A 4783/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | SMN1; SMN2 3286/4885NPC1 1099/4885RAB9A 2106/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | SMN1; SMN2 3286/4885NPC1 1099/4885RAB9A 2106/4885 |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | SMN1; SMN2 1663/4885NPC1 42/4885RAB9A 1029/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | SMN1; SMN2 4114/4885NPC1 4593/4885RAB9A 2131/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | SMN1; SMN2 3286/4885NPC1 1099/4885RAB9A 2106/4885 |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | SMN1; SMN2 2933/4885NPC1 3211/4885RAB9A 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.